REGENERON PHARMACEUTICALS, INC. Accounts Receivable 2009-2026 | REGN
What is accounts receivable?
Accounts receivable represents money owed to the company by customers for goods or services already delivered but not yet paid for.
What is REGENERON PHARMACEUTICALS, INC.'s current accounts receivable?
REGENERON PHARMACEUTICALS, INC. (REGN) annual accounts receivable for 2025 was $5.74B, a 7.58% decline from 2024. REGENERON PHARMACEUTICALS, INC. accounts receivable for the quarter ending March 31, 2026 was $5.73B.
What was REGENERON PHARMACEUTICALS, INC.'s accounts receivable in 2024?
REGENERON PHARMACEUTICALS, INC. annual accounts receivable for 2024 was $6.21B, a 9.61% increase from 2023.
What was REGENERON PHARMACEUTICALS, INC.'s accounts receivable in 2023?
REGENERON PHARMACEUTICALS, INC. annual accounts receivable for 2023 was $5.67B, a 6.35% increase from 2022.
What is REGENERON PHARMACEUTICALS, INC.'s 5-year accounts receivable CAGR?
REGENERON PHARMACEUTICALS, INC. accounts receivable grew at a compound annual growth rate (CAGR) of 6.89% from FY2020 to FY2025, going from $4.11B to $5.74B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $5.74B | -7.6% | 10-K |
| FY2024 | $6.21B | +9.6% | 10-K |
| FY2023 | $5.67B | +6.4% | 10-K |
| FY2022 | $5.33B | -11.7% | 10-K |
| FY2021 | $6.04B | +46.7% | 10-K |
| FY2020 | $4.11B | +95.9% | 10-K |
| FY2019 | $2.10B | +21.8% | 10-K |
| FY2018 | $1.72B | +12.0% | 10-K |
| FY2017 | $1.54B | +14.5% | 10-K |
| FY2016 | $1.34B | +16.6% | 10-K |
| FY2015 | $1.15B | +55.9% | 10-K |
| FY2014 | $739.4M | -6.1% | 10-K |
| FY2013 | $787.1M | +32.7% | 10-K |
| FY2012 | $593.2M | +1999.6% | 10-K |
| FY2011 | $28.3M | +1121.0% | 10-K |
| FY2010 | $2.3M | -19.2% | 10-K |
| FY2009 | $2.9M | - | 10-K |